A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects with Crohn's Disease

A Multi-Center, Randomized, Double-Blind, Placebo-controlled study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects with Crohn's Disease

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220358

Enrollment

Registered

2007-03-12

Start date

2007-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

investigational material(s) Generic name etc : adalimumab INN of investigational material : adalimumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Subjects who successfully enrolled in and completed the M04-729 study Exclusion criteria: - Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study

Exclusion criteria

Exclusion criteria: Exclusion criteria: - Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study

Design outcomes

Primary

Measure	Time frame
Crohn's Disease Activity Index (CDAI)	—

Secondary

Measure	Time frame
IBDQ IOIBD SF-36	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026